ES2884044T3 - Profármaco alquilante de fosforamidato para el tratamiento del cáncer - Google Patents

Profármaco alquilante de fosforamidato para el tratamiento del cáncer Download PDF

Info

Publication number
ES2884044T3
ES2884044T3 ES07869800T ES07869800T ES2884044T3 ES 2884044 T3 ES2884044 T3 ES 2884044T3 ES 07869800 T ES07869800 T ES 07869800T ES 07869800 T ES07869800 T ES 07869800T ES 2884044 T3 ES2884044 T3 ES 2884044T3
Authority
ES
Spain
Prior art keywords
cancer
formulation
dose
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07869800T
Other languages
English (en)
Spanish (es)
Inventor
Steve Ammons
Jian-Xin Duan
Donald Jung
Mark Matteucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmunoGenesis Inc
Original Assignee
ImmunoGenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmunoGenesis Inc filed Critical ImmunoGenesis Inc
Application granted granted Critical
Publication of ES2884044T3 publication Critical patent/ES2884044T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES07869800T 2006-12-26 2007-12-21 Profármaco alquilante de fosforamidato para el tratamiento del cáncer Active ES2884044T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87186506P 2006-12-26 2006-12-26
PCT/US2007/088645 WO2008083101A1 (en) 2006-12-26 2007-12-21 Phosphoramidate alkylator prodrugs for the treatment of cancer

Publications (1)

Publication Number Publication Date
ES2884044T3 true ES2884044T3 (es) 2021-12-10

Family

ID=39588979

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07869800T Active ES2884044T3 (es) 2006-12-26 2007-12-21 Profármaco alquilante de fosforamidato para el tratamiento del cáncer

Country Status (5)

Country Link
US (1) US8552048B2 (enExample)
EP (1) EP2114157B1 (enExample)
JP (1) JP5357049B2 (enExample)
ES (1) ES2884044T3 (enExample)
WO (1) WO2008083101A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
WO2010048330A1 (en) 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
AU2011276590A1 (en) * 2010-06-28 2013-01-31 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
RU2597844C2 (ru) 2010-07-12 2016-09-20 Тресхолд Фармасьютикалз, Инк. Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
MX2013011199A (es) * 2011-04-01 2013-12-16 Threshold Pharmaceuticals Inc Metodos para tratar el cancer.
JP2014510795A (ja) * 2011-04-15 2014-05-01 スレッショルド ファーマシューティカルズ、インク． 経口投与用の単位用量形態物
EP2793882A4 (en) * 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
JP6360438B2 (ja) * 2012-02-21 2018-07-18 モレキュラー テンプレーツ，インコーポレイテッド 癌の治療
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
US20160158253A1 (en) 2013-07-26 2016-06-09 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
WO2016011195A1 (en) * 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
WO2016145092A1 (en) 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
WO2016161342A2 (en) 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US20180169064A1 (en) 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
US20210369746A1 (en) 2016-08-01 2021-12-02 Molecular Templates, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
CA3103205A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
CA3113621A1 (en) * 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
EP3650046A1 (en) 2018-11-08 2020-05-13 Cellis AG Mesenchymal stem cell based targeted active ingredient delivery system
WO2021185986A1 (en) 2020-03-18 2021-09-23 Cellis Ag Ferritin variants with increased stability, complexation ability and transferrin receptor affinity
WO2022195092A1 (en) 2021-03-18 2022-09-22 Cellis Ag Ferritin variants with increased stability and complexation ability
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
JP7762796B2 (ja) * 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
US20260091119A1 (en) 2022-09-13 2026-04-02 Cellis Ag Isolated targeted delivery system for the treatment of glioma
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
EP4637829A1 (en) 2022-12-20 2025-10-29 Cellis Sp. z o.o. ([Ltd.] Isolated targeted delivery system for the treatment of ovarian cancer
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
WO2025083276A1 (en) 2023-10-19 2025-04-24 Cellis Ag Improved isolated targeted delivery system
WO2026120029A1 (en) 2024-12-03 2026-06-11 Cellis Ag Improved isolated targeted delivery system
WO2026132420A1 (en) 2024-12-20 2026-06-25 Cellis Sp. Z O.O. [Ltd.] Isolated targeted delivery system for the treatment of head and neck cancer
WO2026132100A1 (en) 2024-12-20 2026-06-25 Cellis Ag Isolated targeted delivery system for the treatment of bladder cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652579A (en) * 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
DE2229223C3 (de) 1971-07-30 1975-12-18 Gruppo Lepetit S.P.A., Mailand (Italien) 2-Nitro-S-imidazol-Derivate und Verfahren zu deren Herstellung
US4921963A (en) * 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
JPH0819111B2 (ja) * 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US4908356A (en) * 1988-05-25 1990-03-13 Research Corporation Technologies, Inc. Aldophosphamide derivatives useful as antitumor agents
US5403932A (en) * 1988-05-25 1995-04-04 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5190929A (en) * 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
KR927003539A (ko) * 1990-01-26 1992-12-18 스즈끼 쯔네시 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제
US5233031A (en) * 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
JP4115514B2 (ja) * 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
US5750782A (en) * 1992-11-27 1998-05-12 Cancer Research Campaign Technology Limited Nitroaniline derivatives and their use as anti-tumour agents
US5306727A (en) * 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5691371A (en) * 1993-05-25 1997-11-25 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
ES2148259T3 (es) 1993-09-22 2000-10-16 Hoechst Ag Pro-profarmacos, su produccion y uso.
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5659061A (en) 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
US6218519B1 (en) * 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6251933B1 (en) * 1996-12-13 2001-06-26 The Cancer Research Campaign Technology Limited Seco precursors of cyclopropylindolines and their use as prodrugs
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US6240925B1 (en) * 1999-03-23 2001-06-05 Cynosure, Inc. Photothermal vascular targeting with bioreductive agents
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
JP4629238B2 (ja) 1999-05-24 2011-02-09 サザン・リサーチ・インスティテュート イソホスホアミドマスタード・アナログ及びその使用
AU5935600A (en) * 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
DE60117247D1 (de) * 2000-03-31 2006-04-20 Purdue Research Foundation West Lafayette Phosphoramidat-prodrugs
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6506739B1 (en) * 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
KR20030033007A (ko) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
FR2825926A1 (fr) 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR20030067275A (ko) 2002-02-07 2003-08-14 주식회사 하이폭시 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
GB0306908D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US6855695B2 (en) * 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
AU2004285831B2 (en) 2003-10-31 2011-09-15 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
KR20120117943A (ko) 2004-02-06 2012-10-24 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
JP2008520719A (ja) 2004-11-22 2008-06-19 スレショルド ファーマシューティカルズ インコーポレイティッド チューブリン結合抗癌剤およびそれらのプロドラッグ
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
KR100755435B1 (ko) * 2005-10-04 2007-09-04 삼성전자주식회사 디지털 방송 제한 수신 단말기 및 그 방법
WO2008011588A2 (en) 2006-07-20 2008-01-24 Threshold Pharmaceuticals, Inc. Glycoconjugates of phosphoramidate alkylators for treatment of cancer
WO2008076826A1 (en) 2006-12-13 2008-06-26 Threshold Pharmaceuticals, Inc. Pyrophosphoramide alkylators
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer

Also Published As

Publication number Publication date
JP5357049B2 (ja) 2013-12-04
EP2114157B1 (en) 2021-05-26
EP2114157A4 (en) 2013-01-23
JP2010514787A (ja) 2010-05-06
EP2114157A1 (en) 2009-11-11
US8552048B2 (en) 2013-10-08
US20100183742A1 (en) 2010-07-22
WO2008083101A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US8552048B2 (en) Phosphoramidate alkylator prodrugs for the treatment of cancer
ES2719091T3 (es) Terapia de combinación con un inhibidor mitótico
ES2884674T3 (es) Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed
ES2909741T3 (es) Tratamiento del cáncer
ES2258661T3 (es) Formulaciones farmaceuticas con un derivado de platino.
ES2261399T3 (es) Administracion de un compuesto quimioprotector que contiene tiol.
ES2550759T3 (es) Formulaciones farmacológicas de platino mejoradas
EP2063881B1 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
ES2862340T3 (es) Nuevo uso antitumoral de cabazitaxel
US20210267896A1 (en) Formulations for treating bladder cancer
AU2013308465B2 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
KR20020087456A (ko) 혈관 손상 활성을 지닌 조합 요법
ES2745506T3 (es) Combinación antitumoral que comprende cabazitaxel y cisplatino
US20120101057A1 (en) Combined therapy of colorectal carcinoma
CN103623394A (zh) 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
JP5615189B2 (ja) ベリノスタットの長期持続注入を用いた治療方法
EP3010508B1 (en) Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy
US7879814B2 (en) Methods and therapeutic compositions in the treatment of advanced cancer
TW202203938A (zh) 鹼性化學療法瘤內注射調配物
JP2009539774A (ja) 薬物の投与方法
Shinchi et al. A resected case of effective treatment with gemcitabine for advanced pancreatic cancer with peritoneal metastasis
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
ES2594499A1 (es) Complejos de Rutenio para el tratamiento del cáncer